Multivalent Meningiococcal Conjugates and Methods for Preparing Conjugates
Posted Jan 22 2013 7:00pm
Description of Invention: Among 13 isolated meningococcal serogroups, A, B, C, W-135 and Y are the most prevalent. There are three FDA-approved capsular polysaccharide (PS)-based vaccines, one tetravalent PS vaccine, and two tetravalent conjugate vaccines for protection against meningococcal disease caused by groups A, C, W-135 and Y Neisseria meningitidis. Group B capsular PS is similar to the PS structure expressed in certain human tissues, thus making it a poor immunogen. Furthermore, if used as a vaccine, the possibility exists of it inducing an autoimmune response. Thus, a need remains to develop additional meningococcal vaccines, particularly for group B and group X meningococcal serogroups.
This application claims immunogenic conjugates including at least one polysaccharide conjugated to a group B factor H binding protein (fHbp). Also claimed are immunogenic conjugates including at least one polysaccharide conjugated to a Neisserial surface protein A (NspA). Additionally, improved methods for preparing conjugates are claimed.
Multivalent meningitis vaccine
Higher vaccine yield
More efficient conjugation method
Lower cost vaccines
In vitro data available
In vivo data available (animal)
Inventors: Che-Hung Robert Lee (FDA) Vavlerian Pinto (Walter Reed Army Institute of Research) Elizabeth E Moran (Walter Reed Army Institute of Research) Robert E Burden (Walter Reed Army Institute of Research)
Collaborative Research Opportunity: The FDA/CBER is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Multivalent Meningiococcal Conjugates and Methods for Preparing Conjugates. For collaboration opportunities, please contact Che-Hung Robert Lee at email@example.com or 301-451-5934.
For Licensing Information Please Contact: Peter Soukas J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 14, Rockville, MD 20852-3804 United States Email: firstname.lastname@example.org Phone: 301-435-4646 Fax: 301-402-0220